Zacks Research Has Negative Outlook for ACAD Q1 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Tuesday, March 18th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.09 per share for the quarter, down from their previous forecast of $0.14. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ Q4 2025 earnings at $0.19 EPS, FY2025 earnings at $0.68 EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.26 EPS, Q3 2026 earnings at $0.32 EPS, Q4 2026 earnings at $0.33 EPS, FY2026 earnings at $1.01 EPS and FY2027 earnings at $1.37 EPS.

Several other analysts also recently weighed in on ACAD. Guggenheim downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. StockNews.com raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $20.00 price target on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Eight analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $24.00.

ACADIA Pharmaceuticals Price Performance

Shares of ACADIA Pharmaceuticals stock opened at $16.79 on Thursday. The business’s fifty day moving average price is $18.37 and its two-hundred day moving average price is $17.00. The company has a market capitalization of $2.80 billion, a P/E ratio of 21.53 and a beta of 0.43. ACADIA Pharmaceuticals has a 1-year low of $14.15 and a 1-year high of $20.68.

Insider Buying and Selling

In related news, Director Elizabeth A. Garofalo sold 4,919 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the transaction, the director now directly owns 17,595 shares of the company’s stock, valued at approximately $320,756.85. The trade was a 21.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 6,167 shares of company stock worth $114,583 in the last three months. 28.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in ACADIA Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 13,947,640 shares of the biopharmaceutical company’s stock valued at $255,939,000 after buying an additional 104,444 shares during the period. State Street Corp raised its position in ACADIA Pharmaceuticals by 3.0% during the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company’s stock valued at $91,878,000 after buying an additional 173,084 shares during the period. Fred Alger Management LLC grew its stake in ACADIA Pharmaceuticals by 17.8% in the third quarter. Fred Alger Management LLC now owns 3,186,389 shares of the biopharmaceutical company’s stock valued at $49,007,000 after purchasing an additional 481,950 shares in the last quarter. Geode Capital Management LLC grew its stake in ACADIA Pharmaceuticals by 1.1% in the third quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company’s stock valued at $44,234,000 after purchasing an additional 30,826 shares in the last quarter. Finally, First Trust Advisors LP grew its stake in ACADIA Pharmaceuticals by 27.0% in the fourth quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company’s stock valued at $49,547,000 after purchasing an additional 574,251 shares in the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.